Telik, Inc. (TELK) announced that the U.S. Food and Drug Administration or FDA has removed the partial hold on TELCYTA (canfosfamide HCl, TLK286) clinical trials. The company said that this action follows a complete review of TELCYTA data by the agency and permits the resumption of TELCYTA clinical development.The company noted that its most advanced drug development candidates are TELCYTA, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non- small cell lung cancer; and TELINTRA, which is in clinical development for the treatment of myelodysplastic syndrome.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.